Published in J Immunol on November 01, 1980
Immunotherapeutic approaches for glioma. Crit Rev Immunol (2009) 1.55
Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest (1987) 1.04
Transmembrane signaling by the B subunit of cholera toxin: increased cytoplasmic free calcium in rat lymphocytes. J Cell Biol (1987) 1.01
Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc Natl Acad Sci U S A (1994) 0.94
Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand. Immunology (2008) 0.90
Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry. Front Oncol (2012) 0.87
Role of GM3-enriched microdomains in signal transduction regulation in T lymphocytes. Glycoconj J (2004) 0.87
Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro. J Clin Invest (1984) 0.85
Gangliosides inhibit the development from monocytes to dendritic cells. Clin Exp Immunol (2002) 0.83
Hemolysis of human erythrocytes is a new bioactivity of gangliosides. J Exp Med (1991) 0.79
Activation of human T lymphocytes by ganglioside-containing liposomes. Glycoconj J (1999) 0.75
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer (1997) 3.58
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg (1998) 2.75
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest (1997) 2.33
Effects of interleukin-1 on bone turnover in normal mice. Endocrinology (1989) 2.06
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med (1996) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol (1995) 1.94
Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol (2001) 1.91
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med (1998) 1.84
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group. J Neurooncol (1998) 1.48
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med (2000) 1.47
Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed) (1985) 1.45
Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res (2001) 1.45
Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet (1985) 1.42
Is alendronate clinically gastrotoxic? Re: Graham et al. primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Am J Gastroenterol (1998) 1.40
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol (1987) 1.34
Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics. Ann Neurol (1989) 1.28
Characteristics of cyclosporine induction of increased prostaglandin levels from human peripheral blood monocytes. Transplantation (1984) 1.28
A preoperative decolonization protocol for staphylococcus aureus prevents orthopaedic infections. Clin Orthop Relat Res (2008) 1.26
Urology in a modern health centre. Br Med J (1975) 1.26
Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol (1985) 1.20
Diphosphonates and phosphate homoeostasis in man. Clin Sci (Lond) (1988) 1.20
Creutzfeldt-Jakob disease presenting as progressive aphasia. J Natl Med Assoc (1985) 1.18
Brain tumors in childhood. Childs Brain (1979) 1.15
Redox signals and NF-kappaB activation in T cells. Free Radic Biol Med (1998) 1.15
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab (1996) 1.15
Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J (Clin Res Ed) (1984) 1.14
Body size accounts for most differences in bone density between Asian and Caucasian women. The EPIC (Early Postmenopausal Interventional Cohort) Study Group. Calcif Tissue Int (1996) 1.13
An immunophenotypic survey of malignant melanomas. Histopathology (1993) 1.13
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol (1996) 1.13
Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone (1987) 1.12
The syndrome of occult rupture of the spleen. Arch Surg (1969) 1.12
The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab (1993) 1.11
Heterogeneity of murine regulatory T cells. I. Subpopulations of amplifier and suppressor T cells. J Exp Med (1976) 1.11
Endogenous GD3 ganglioside induces apoptosis in U-1242 MG glioma cells. J Neurochem (2006) 1.10
Clinical and biochemical abnormalities in coppersmiths exposed to cadmium. Lancet (1976) 1.10
Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J (Clin Res Ed) (1984) 1.07
Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab (1999) 1.05
Psychological deficit. Annu Rev Psychol (1966) 1.04
Suppression of humoral and delayed hypersensitivity responses by distinct T cell subpopulations. J Immunol (1978) 1.04
Effective short term treatment of Paget's disease with oral etidronate. Br Med J (Clin Res Ed) (1986) 1.03
Treatment of high-grade spinal cord astrocytoma of childhood with "8-in-1" chemotherapy and radiotherapy: a pilot study of CCG-945. Children's Cancer Group. J Neurosurg (1998) 1.02
Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res (1997) 1.02
Intracranial chordoma in infancy. Case report. J Neurosurg (1975) 1.02
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone (1996) 1.00
Relation of axon membrane to myelin membrane in sciatic nerve during development: comparison of morphological and chemical parameters. Brain Res (1976) 1.00
Boron neutron capture therapy of a rat glioma. Neurosurgery (1990) 0.98
Heterogeneity of human monocyte subsets in the promotion of B cell colonies and the role of interleukin 1. J Immunol (1982) 0.98
A study of intracellular orthophosphate concentration in human muscle and erythrocytes by 31P nuclear magnetic resonance spectroscopy and selective chemical assay. Clin Sci (Lond) (1986) 0.96
Measuring serum calcium. Br Med J (Clin Res Ed) (1985) 0.96
Phenotypic characteristics of peripheral blood T cells regulating colony growth by nontransformed human B lymphocytes. J Immunol (1983) 0.95
Sublethal levels of oxidative stress stimulate transcriptional activation of c-jun and suppress IL-2 promoter activation in Jurkat T cells. J Immunol (1996) 0.94
Bolus injections of recombinant human interleukin-1 cause transient hypocalcemia in normal mice. Endocrinology (1989) 0.94
Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J Med Genet (2000) 0.93
Lipid composition of human neural tumors. J Lipid Res (1979) 0.93
In vivo effects of human recombinant transforming growth factor beta on bone turnover in normal mice. J Bone Miner Res (1990) 0.92
Optimal NF kappa B mediated transcriptional responses in Jurkat T cells exposed to oxidative stress are dependent on intracellular glutathione and costimulatory signals. Biochem Biophys Res Commun (1996) 0.92
Prediction of fracture risk by radiographic absorptiometry and quantitative ultrasound: a prospective study. Calcif Tissue Int (1998) 0.92
Pathological lesions in the spontaneously diabetic BB Wistar rat: a comprehensive autopsy study. Metabolism (1983) 0.91
Brainstem immaturity in sudden infant death syndrome: a quantitative rapid Golgi study of dendritic spines in 95 infants. Brain Res (1985) 0.91
Treatment of malignant hypercalcaemia with clodronate. Br J Cancer (1985) 0.90
A comparative study of the glycolipids of human, bird and fish testes and of human sperm. Biochim Biophys Acta (1976) 0.89
A review and predictive models of ganglioside uptake by biological membranes. J Neurochem (1993) 0.89
Irreducible dorsal interphalangeal great toe dislocation. Orthopedics (1992) 0.88
Gangliosides inhibit platelet-derived growth factor-stimulated growth, receptor phosphorylation, and dimerization in neuroblastoma SH-SY5Y cells. J Neurochem (1995) 0.87
Age-related defects in Th1 and Th2 cytokine production by human T cells can be dissociated from altered frequencies of CD45RA+ and CD45RO+ T cell subsets. Mech Ageing Dev (1999) 0.87
Glycolipids and myelin proteins in human oligodendrogliomas. Glycoconj J (1996) 0.87
Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med (1987) 0.87
Gangliosides inhibit growth factor-stimulated neurite outgrowth in SH-SY5Y human neuroblastoma cells. J Neurosci Res (1997) 0.87
Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab (2000) 0.87
Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group. Med Pediatr Oncol (1999) 0.86
Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res (2000) 0.86
A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group. Am J Clin Nutr (1996) 0.85
Gangliosides inhibit platelet-derived growth factor-stimulated receptor dimerization in human glioma U-1242MG and Swiss 3T3 cells. J Neurochem (1993) 0.85
Treatment of the hypercalcaemia of malignancy with intravenous clodronate. Bone (1987) 0.84
Aminohexane diphosphonate in the treatment of Paget's disease of bone. J Bone Miner Res (1987) 0.84
Reiter's aortitis with pericardial fluid, heart block and neurologic manifestations. J Rheumatol (1979) 0.84
Inhibition of human B lymphocyte colony responses by endogenous synthesized hydrogen peroxide and prostaglandins. Cell Immunol (1982) 0.83
Control of cyclic adenosine 3',5'-monophosphate production in osteoclasts: calcitonin-induced persistent activation and homologous desensitization of adenylate cyclase. Endocrinology (1987) 0.83
Circulatory arrest during profound hypothermia. For treatment of complicated disease of major vessels. Arch Surg (1971) 0.83
Postmorten changes in the chemistry and histology of normal and edematous brains. Am J Pathol (1975) 0.83
Pre-irradiation chemotherapy in children with high-grade astrocytoma: tumor response to two cycles of the '8-drugs-in-1-day' regimen. A Childrens Cancer Group study, CCG-945. J Neurooncol (1994) 0.83
Natural killer cells against human corneal endothelium. Am J Ophthalmol (1985) 0.83
Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine. J Immunol (1983) 0.82
The histopathological features of asymptomatic hepatitis C virus-antibody positive blood donors. Histopathology (1994) 0.82
Paget's disease of bone. Baillieres Clin Endocrinol Metab (1988) 0.82
Correlation of ganglioside patterns of primary brain tumors with survival. Cancer (1995) 0.82
Ganglioside composition and histology of a spontaneous metastatic brain tumour in the VM mouse. Br J Cancer (2001) 0.82
The impaired ability of human monocytes to stimulate autologous and allogeneic mixed lymphocyte reactions after exposure to cyclosporine. Associated alterations of HLA-DR expression and physical characteristics of monocytes. Transplantation (1985) 0.82
Cell cycle phases of the novel human neural cell line and the effect of exogenous gangliosides. Biochem Biophys Res Commun (1982) 0.82
Gangliosides in the nervous system during development and regeneration. Neurochem Pathol (1986) 0.82
Syndrome of inappropriate antidiuretic hormone secretion in association with temporal arteritis. J Rheumatol (1983) 0.82
Differential abilities of human peripheral blood monocytes quantitatively or qualitatively differing in HLA-DR and HLA-DS expression to support B cell activation in liquid and semisolid cultures. J Immunol (1985) 0.81
Critical study of the alditol acetate method for quantitating small quantities of hexoses and hexosamines in gangliosides. J Chromatogr (1980) 0.81
Changes in the sciatic nerve of the rabbit and its tissue constituents during development. J Neurochem (1974) 0.81